Stevanato Group (NYSE:STVN) today announced a collaboration with Thermo Fisher Scientific (NYSE:TMO) on drug delivery technology. The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market. Stevanato Group said the device will be semi-reusable and provide micro-precision basal doses and full-content bolus injections. The company intends for the […]
stevanato group
Stevanato Group, Recipharm partner on pre-filled syringes for inhaled therapeutics
Stevanato Group (NYSE:STVN) today announced a collaboration with Recipharm to manufacture pre-fillable syringes for soft mist inhalers. Piombino Dese, Italy-based Stevanato Group plans to lend manufacturing experience to support production of the syringes. As part of the collaboration, it intends to provide and manufacture its Alba glass pre-fillable syringe. Stevanato Group will assemble Alba with […]
Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector
Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology. Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with market-leading pre-filled syringes. […]
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder […]
Stevanato Group acquires facility set to become manufacturing hub in China
Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant. Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development. Get […]
Stevanato Group extends licensing agreement with Haselmeier for pen injector tech
Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology. Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas such […]
FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump
Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. Get the full story at our sister site, Drug Delivery Business News.
Stevanato Group expands corporate headquarters
Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy. Based in Piombino Dese, Italy, Stevanato Group expects its 6,750-square-meter facility to support the optimization of its industrial footprint while advancing operations and growth within the company. Get the full story at our sister site, Drug Delivery Business News.
Stevanato Group beats The Street in Q3, raises guidance
Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast. The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of 36.5%. […]
Stevanato Group is constructing a new facility in Indiana
Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana. Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023. Get the full story at our sister site, Drug Delivery Business News.
MedTech 100 roundup: On the rise again
After a slight hiccup disrupted weeks of improvement, the medtech industry again flexed its muscles over the last seven days. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 20) at 119.63 points, representing a 1.5% rise from the 117.92-point tally set a week prior. […]
